GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year.
To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs.
GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights.
GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan:
Louis-Marie is a biotech entrepreneur with 15 years of experience in the field of innovative therapies and rare diseases;
Claire, specialist of the neuronal cytoskeleton, has sound knowledge of preclinical experimental techniques;
Its Scientific & Medical Advisory Board is composed of leading international experts in research and treatment of glioblastoma.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Angers
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gliocure.com
- Keywords
- Glioblastoma, Glioma, Neurooncology, Innovative therapies, Nanomedicines, Rare diseases, Neurosurgery, Brain tumors, Orphan drugs, Peptide.
- HQ
- Angers
Gliocure Questions
Gliocure's website is gliocure.com
Gliocure's LinkedIn profile is https://fr.linkedin.com/company/gliocure
Gliocure has
5 employees.
View email and phone details for 5
employees at Gliocure.
Gliocure's industry is
Biotechnology Research
Gliocure's top competitors are
Atlanthera,
I-Sep,
Xenothera,
Goliver Therapeutics,
Association Des Étoiles Dans La Mer, Vaincre Le Glioblastome,
Cellectis,
Naobios,
Affilogic,
Gensensor,
Atlanpole Biotherapies.
Gliocure's categories are Biotechnology Research
Gliocure's founding year is 2016
